Pro 2013-004 (Jianfeng Group's First Extraordinary Shareholders' Meeting in 2013)
Release time:
2020-08-05
Stock Abbreviations: Jianfeng Group Stock Code: 600 66 8 No: pro 20 13 -0 04
Zhejiang Jianfeng Group Co., Ltd.
Resolution Announcement of the First Extraordinary General Meeting of Shareholders in 2013
The Board of Directors and all directors of the Company guarantee that the contents of this announcement do not contain any false records or misleading statements or material omissions, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents . |
Important Content Note:
1 , No Rejection or Modification of Proposals at this Meeting;
2 , no new proposal submitted for vote at this meeting.
1. Meeting and Attendance
Zhejiang Jianfeng Group Co., Ltd. The first extraordinary shareholders' meeting in 2013 was held on the spot on January 22, 2013 at Jianfeng Building, 88 Wujiang East Road, Jinhua City, Zhejiang Province. The notice of this meeting was published in china securities journal and shanghai securities news on January 5, 20 13. The meeting was convened by the board of directors of the company and presided over by Mr. Jiang Xiaomeng, chairman of the board of directors.
There were 8 shareholders and shareholder representatives, representing 55719117 shares, accounting for 16.19 of the company's total share capital. Some directors, supervisors and senior executives of the company attended the meeting, and the company's legal counsel attended and witnessed the meeting. The convening of the meeting, held in line with the company law, the articles of association of the company.2. Proposal Review
This meeting deliberated and passed the following proposals by secret ballot and item by item:
1
, "Proposal on the Company's Compliance with the Conditions for Issuing Corporate Bonds"
Voting Results: Agree55719117 Shares, 100 per cent of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;opposed 0 shares, accounting for 0% of the voting shares present at the meeting.
2
and reviewed and approved the Proposal on Issuing Corporate Bonds Item by Item;
2.Issue Scale
Voting Result: Agreed55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
2.
2 Placing Arrangement to Original Shareholders of the Company
Voting Results: Agree to55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;opposes 0 shares, 0% of the number of voting shares present.
2.
3 Bond Term
Voting Result: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;Opposes 0 Shares, 0% of the number of voting shares present.
2.
4 Bond Interest Rate and Determination Method
Voting Result: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;Opposes 0 Shares, 0% of the number of voting shares present.
2.
5 Issuance Method
Voting Result: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;Opposes 0 Shares, 0% of the number of voting shares present.
2.
6 Issuing Object
Voting Result: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;Opposes 0 Shares, 0% of the number of voting shares present.
2.7
Guarantee Arrangement
Voting Result: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
2.8
Use of Funds Raised
Voting Results: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
2.9
Bond Issuance Listing
Voting Results: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
2.10
Resolution Validity Period
Voting Results: Agree55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, accounting for 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
3
and "Proposal on Requiring the General Meeting of Shareholders of the Company to Authorize the Board of Directors and its Authorized Persons to Fully Handle Matters Related to the Issuance of Corporate Bonds"
Voting Results: Agree to55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
4
, "Proposal on Requiring the General Meeting of Shareholders of the Company to Authorize the Board of Directors to Take Repayment Safeguard Measures in the Case of Expected Failure to Pay the Bond principal and Interest on Time or Failure to Pay the Bond principal and Interest on Time"
Voting Result: Agree to55719117 shares, accounting for 100 of the voting shares present at the meeting;
abstained from 0 shares, 0% of the voting shares present at the meeting;against 0 shares, accounting for 0% of the voting shares present at the meeting.
3. Lawyer's Witness
Lawyers Chen Xiongwu and Zuo Wenhui of Zhejiang Yijian Law Firm witnessed the shareholders' meeting on the spot and issued legal opinions, believing that: "
Zhejiang Jianfeng Group Co., Ltd. the convening and convening procedures of the first extraordinary general meeting of shareholders in 2013 , the qualifications of the participants, the proposals and voting procedures of this general meeting of shareholders, etc., all comply with laws, Regulations and the relevant provisions of the" Articles of Association ", the Resolution of this general meeting of shareholders is legal and valid. "
4. Reference Document Catalogue1
, "Resolution of the First Extraordinary General Meeting of Zhejiang Jianfeng Group Co., Ltd. in 2013" signed and confirmed by the participating directors
2, Zhejiang Yijian Law Firm "Law on the First Extraordinary General Meeting of Zhejiang Jianfeng Group Co., Ltd. in 2013 opinion .
hereby announceZhejiang Jianfeng Group Co., Ltd.
Board of Directors
January 22, 2013
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page